DSM Venturing, the corporate venturing unit of Royal DSM N.V., has participated in a US$20 mln financing round in Tianjin Green Bio-Science Co., Ltd (China), to build China's largest manufacturing plant for Polyhydroxyalkanoates (PHA). Construction will commence in Q2 2008, with production estimated in early 2009. Annual production is being targeted at 10,000 tons of PHA. The company has earmarked up to EUR 200 million for venturing investments until 2012. China is one of the core regions in the global investment strategy of DSM Venturing.
As PHA is produced through fermentation by micro-organisms, it also offers the opportunity for DSM to extend its competencies both in Life Sciences and Material Sciences to a new family of biopolymers. The investment is in line with DSM's ambitions to develop bio-based performance materials to meet customers' growing needs for improved performance and environmental benefits at competitive costs. PHA offers, in response to the growing market need for eco-friendly solutions, a new biorenewable polymer platform for a broad range of applications from automotive to biomedical and electronics, including multiple forms like fibers, films and foams.
Years of research and development has made Tianjin Green Bio-Science a leader within China for the production, extraction, processing and application of PHA.